The UK and US have established a significant bilateral deal that will guarantee zero duties on British medicine exports going into the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on medicines through the NHS. This pledge ensures that tariffs on these vital goods will be held at zero for a period of 36 months.
This deal is in response to previous warnings to significantly raise import taxes on branded drug products, with potential rates discussed as high as double the cost.
"This arrangement between the UK reinforces the international landscape for cutting-edge drugs and establishes much-needed equity to transatlantic pharmaceutical trade," a release noted.
Trade Impact
Pharmaceuticals are one of the Britain's most significant export categories to the America, which is clearly the biggest buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of last September, the UK sold drugs totaling £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that span.
"This deal protects employment, increases capital expenditure and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister remarked.
Specific NHS Changes
The deal includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to double total NHS spending on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount drug companies must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments exceeded twenty percent.
Industry Background
This agreement comes amid a ongoing row between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that American customers were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward US facilities.
One official publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
